--- title: "Sinopharm Subsidiary Posts 2025 Revenue Growth Amid Flat Earnings and Stronger Cash Flow" type: "News" locale: "en" url: "https://longbridge.com/en/news/279810360.md" description: "Sinopharm Group Co. has reported its 2025 financial results for its subsidiary, China National Medicines Corporation. Revenue increased by 3.7% to RMB 52.47 billion, while net profit fell slightly by 0.18% to RMB 1.997 billion, with earnings per share remaining stable. The subsidiary improved cash flow, with net operating cash flow rising by 20.88%. Despite a decline in return on net assets, total assets grew by 5.03%. Analysts rate the stock as a Buy with a target price of HK$23.00." datetime: "2026-03-19T14:11:02.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/279810360.md) - [en](https://longbridge.com/en/news/279810360.md) - [zh-HK](https://longbridge.com/zh-HK/news/279810360.md) --- # Sinopharm Subsidiary Posts 2025 Revenue Growth Amid Flat Earnings and Stronger Cash Flow ### Claim 70% Off TipRanks Premium - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Sinopharm Group Co ( (HK:1099) ) has issued an update. Sinopharm Group has disclosed the 2025 audited financial results of its Shanghai-listed subsidiary China National Medicines Corporation, showing modest top-line growth but largely flat profitability. Revenue rose 3.7% year on year to RMB 52.47 billion, while net profit attributable to shareholders slipped 0.18% to RMB 1.997 billion, and earnings per share were essentially unchanged. Despite the slight earnings decline, SINOPHARM CNCM improved its cash generation, with net operating cash flow up 20.88% versus 2024 and net assets attributable to shareholders increasing 8.27%. The weighted average return on net assets fell by nearly one percentage point, indicating some margin pressure even as total assets expanded 5.03%, suggesting steady but moderating profitability for stakeholders in a growing asset base. The most recent analyst rating on (HK:1099) stock is a Buy with a HK$23.00 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page. **More about Sinopharm Group Co** Sinopharm Group Co. is a major Chinese pharmaceutical and healthcare company, with its subsidiary China National Medicines Corporation Ltd. (SINOPHARM CNCM) engaged in the distribution and trade of medicines and related healthcare products. The subsidiary’s A shares are listed on the Shanghai Stock Exchange, positioning it as a significant player in China’s pharmaceutical supply chain. **Average Trading Volume:** 5,305,954 **Technical Sentiment Signal:** Strong Buy **Current Market Cap:** HK$65.72B For an in-depth examination of 1099 stock, go to TipRanks’ Overview page. ### Related Stocks - [000028.CN](https://longbridge.com/en/quote/000028.CN.md) - [600056.CN](https://longbridge.com/en/quote/600056.CN.md) - [600511.CN](https://longbridge.com/en/quote/600511.CN.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) - [588860.CN](https://longbridge.com/en/quote/588860.CN.md) - [516820.CN](https://longbridge.com/en/quote/516820.CN.md) - [588130.CN](https://longbridge.com/en/quote/588130.CN.md) - [510660.CN](https://longbridge.com/en/quote/510660.CN.md) - [588250.CN](https://longbridge.com/en/quote/588250.CN.md) - [512010.CN](https://longbridge.com/en/quote/512010.CN.md) - [159859.CN](https://longbridge.com/en/quote/159859.CN.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) - [516500.CN](https://longbridge.com/en/quote/516500.CN.md) - [159929.CN](https://longbridge.com/en/quote/159929.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) ## Related News & Research - [Sinopharm subsidiary posts steady Q1 profit growth but cash flow weakens](https://longbridge.com/en/news/283669573.md) - [HBM Holdings Says Director Probed by CSRC, Sees No Impact on Operations](https://longbridge.com/en/news/286197909.md) - [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md) - [Manulife Singapore to offer multi-cancer blood test starting May](https://longbridge.com/en/news/286710691.md) - [Fingerprint Cards AB Bets on Merger-Led Turnaround](https://longbridge.com/en/news/286333864.md)